Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21814329 | 1.00 | TP53 (0.36) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL8637228 | 1.00 | TP53 (0.36) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL16877112 | 0.86 | — | — | |
| SCHEMBL13169085 | 0.78 | TP53 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| Cyclohexane SCHEMBL5838004 | 0.78 | TP53 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL20354169 | 0.78 | KDM4E (0.42) | TP53KDM4E | |
| SCHEMBL4756623 | 0.78 | TP53 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL6548556 | 0.78 | TP53 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL9318873 | 0.75 | METAP1 (0.47) | TP53 | |
| SCHEMBL20038792 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425009-A4 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | IVAX INST FOR DRUG RES LTD (HU) | 2006-10-25 | — | — | EP | disclosed |
| US-20050070480-A1 | Peptide arginals and methods for treating disseminated intravascular coagulation | IVAX DRUG RESEARCH INSTITUTE LTD. (HU) | 2005-03-31 | — | — | US | disclosed |
| EP-1425009-A2 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | Ivax Institute for Drug Research, Ltd. (HU) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003016273-A2 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | IVAX CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070480-A1 | Peptide arginals and methods for treating disseminated intravascular coagulation | ARGLU1, PLAT, SERPINC1 | TP53 2734/4885KDM4E 2547/4885GMNN 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.